A First-in-human, Phase I Study of Evaluating Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AK138D1 in the Treatment of Advanced Solid Tumors
Latest Information Update: 18 Dec 2024
Price :
$35 *
At a glance
- Drugs AK 138D1 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Akeso Biopharma
- 18 Dec 2024 New trial record